Advancing the defensive explanation for anxiety disorders: Lorazepam effects on human defense are systematically modulated by personality and threat-type

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Perkins, A M ^a   Ettinger, U ^b   Weaver, K ^a   Schmechtig, A ^a   Schrantee, A ^c   Morrison, P D ^a   Sapara, A ^a   Kumari, V ^a   Williams, S C R ^a   Corr, P J ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BONN   (Germany)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d CITY UNIVERSITY   (United Kingdom)

Author keywords

Anxiety; Fear; Flight; Human Defense; Lorazepam; Risk Assessment

Indexed keywords

LORAZEPAM; PLACEBO; ANXIOLYTIC AGENT;

ANXIETY DISORDER; ARTICLE; AVERSIVE BEHAVIOR; AVOIDANCE BEHAVIOR; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEAR; FEAR SURVEY SCHEDULE; FEMALE; FLIGHT; HUMAN; HUMAN EXPERIMENT; MALE; NEUROSIS; NORMAL HUMAN; PERCEPTION; PERSONALITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPECIES DIFFERENCE; SPIELBERGER TRAIT ANXIETY; THREAT; ESCAPE BEHAVIOR; HIGH RISK BEHAVIOR; PERSONALITY TEST; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; YOUNG ADULT; ANXIETY DISORDERS; DRUG EFFECTS; PSYCHOLOGY;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCAPE REACTION; FEAR; FEMALE; HUMANS; LORAZEPAM; MALE; PERSONALITY; PERSONALITY INVENTORY; PSYCHOLOGICAL TESTS; RISK-TAKING; YOUNG ADULT;

EID: 84878637071     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.20     Document Type: Article

References (46)

1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655-679.
2. Claridge G, Davis C. What's the use of neuroticism? Pers Indiv Differ 2001; 31: 383-400. (Pubitemid 33619575)
3. Blanchard DC, Blanchard RJ. Defensive behaviors, fear and anxiety. In Blanchard RJ, Blanchard DC, Griebel G, Nutt D (eds). Handbook of Anxiety and Fear. Academic: Amsterdam, The Netherlands, 2008; vol 17, pp 63-79.
4. Blanchard DC, Hynd AL, Minke KA, Minemoto T, Blanchard RJ. Human defensive behaviors to threat scenarios show parallels to fear-and anxiety-related defense patterns of non-human mammals. Neurosci Biobehav Rev 2001; 25: 761-770. (Pubitemid 34136904)
5. Gray JA, McNaughton N. The Neuropsychology of Anxiety: an Enquiry into the Functions of the Septo-Hippocampal System. OUP: Oxford, UK, 2000.
6. Blanchard DC, Blanchard RJ, Rodgers RJ. Risk assessment and animal models of anxiety. In Olivier B, Mos J, Slangen JL (eds) Animal Models in Psychopharmacology. Birkha? user: Basel, Switzerland, pp 117-134, 1991.
7. Matthews G. Reinforcement sensitivity theory: a critique from cognitive science. In Corr PJ (ed). The Reinforcement Sensitivity Theory of Personality. Cambridge University Press: Cambridge, UK, pp 482-507, 2008.
8. Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B et al. When fear is near: threat imminence elicits prefrontal-periaqueductal grey shifts in humans. Science 2007; 317: 1079-1083. (Pubitemid 47330191)
9. Mobbs D, Marchant JL, Hassabis D, Seymour B, Tan G, Gray M et al. From threat to fear: the neural organization of defensive fear systems in humans. J Neurosci 2009; 29: 12236-12243.
10. Mobbs D, Yu R, Rowe JB, Eich H, FeldmanHall O, Dalgleish T. Neural activity associated with monitoring the oscillating threat value of a Tarantula. Proc Natl Acad Sci USA 2010; 107: 20582-20586.
11. Perkins AM, Ettinger U, Williams SCR, Reuter M, Hennig J, Corr PJ. Flight behaviour in humans is intensified by a candidate genetic risk factor for panic disorder: evidence from a translational model of fear and anxiety. Mol Psychiatr 2011; 16: 242-244.
12. Perkins AM, Ettinger U, Davis R, Foster R, Williams SCR, Corr PJ. Effects of lorazepam and citalopram on human defensive reactions: ethopharmacological differentiation of fear and anxiety. J Neurosci 2009; 29: 12617-12624.
13. McNaughton N, Corr PJ. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci Biobehav Rev 2004; 28: 285-305. (Pubitemid 38844377)
14. Gould RA, Otto MW, Pollack MH, Yap L. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Behav Ther 1997; 28: 285-305. (Pubitemid 27422460)
15. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatr 1997; 170: 549-553. (Pubitemid 27418096)
16. Griebel G, Blanchard DC, Jung A, Blanchard RJ. A model of antipredator defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 1995; 6: 732-745.
17. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O et al. Stimulation of the b3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008; 33: 574-587.
18. van Ruitenbeek P, Vermeeren A, Riedel WJ. Memory in humans is unaffected by central H1-antagonism, while objectively and subjectively measured sedation is increased. Eur Neuropsychopharmacology 2010; 20: 226-235.
19. Eysenck HJ, Eysenck SBG. Eysenck Personality Scales (EPS Adult). Hodder & Stoughton: London, UK, 1991.
20. Spielberger CD, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory: STAI (Form Y2). Consulting Psychologists: Palo Alto, CA, 1983.
21. Wolpe J, Lang PJ. Manual for the Fear Survey Schedule. Educational and Industrial Testing Service: San Diego, CA, 1977.
22. Griebel G, Sanger DJ, Perrault G. Genetic differences in the mouse defense test battery. Aggress Behav 1997; 23: 19-31. (Pubitemid 127355905)
23. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 1995; 120: 57-66.
24. Mackinnon A, Jorm AF, Christensen H, Korten AE, Jacomb PA, Rodgers B. A short form of the positive and negative affect schedule: evaluation of factorial validity and invariance across demographic variables in a community sample. Pers Ind Diff 1999; 27: 405-416.
25. de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM. Biomarkers for the effects of benzodiazepines in healthy volunteers. Brit J Clin Pharmacol 2003; 55: 39-50. (Pubitemid 36110838)
26. Reilly JL, Lencer R, Bishop JR, Keedy S, Sweeney JA. Pharmacological treatment effects on eye movement control. Brain Cognition 2008; 68: 415-435.
27. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiat 1994; 51: 8-19.
28. Corr PJ. Approach and avoidance behavior: Multiple systems and their interactions. Emotion Review 2013; 5 (in press).
29. Davis M,Walker DL, Miles L, Grillon C. Phasic vs. sustained fear in rats and humans: Role of the extended amygdala in fear vs. anxiety. Neuropsychopharmacology 2010; 35: 105-113.
30. Blanchard DC, Griebel G, Blanchard RJ. The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 2003; 463: 97-116. (Pubitemid 36205074)
31. Patrick CJ, Berthot BD, Moore JD. Diazepam blocks fear-potentiated startle in humans. J Abnorm Psychol 1996; 105: 89-96. (Pubitemid 26039294)
32. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Barbanoj MJ. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a doseresponse study. Psychopharmacology 2001; 157: 358-367. (Pubitemid 32988482)
33. Thornton JC, Kumari V, Cotter PA, Kaviani H, Checkley SA, Wilson GD et al. Effects of 5 mg and 15 mg oral diazepam on modulation of the human startle reflex by emotionallytoned film clips. J Psychophysiol 1999; 13: 141-142.
34. Hofmeijer-Sevink MK, Batelaan NM, van Megen HJ, Penninx BW, Cath DC, van den Hout MA et al. Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord 2012; 137: 106-112.
35. Eysenck HJ. The Biological Basis of Personality. Charles C. Thomas: Springfield, Illinois, 1967.
36. Markon KE, Krueger RF, Watson D. Delineating the structure of normal and abnormal personality: An integrative hierarchical approach. J Pers Soc Psychol 2005; 88: 139-157. (Pubitemid 40131539)
37. Goisman RM, Goldenberg I, Vasile RG, Keller MB. Comorbidity of anxiety disorders in a multicenter anxiety study. Compr Psychiat 1995; 36: 303-311.
38. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiat 1989; 50: 418-423. (Pubitemid 19282226)
39. Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK et al. Lorazepam v alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990; 23: 65.
40. Ballenger JC. Efficacy of benzodiazepines in panic disorder and agoraphobia. J Psychiatr Res 1990; 24(Suppl 2): 15-25. (Pubitemid 20374693)
41. Deakin JFW, Graeff FG. 5-HT and mechanisms of defence. J. Psychopharmacology 1991; 5: 305-315.
42. LeDoux JE. Emotion, memory and the brain. Sci Am 1994; 270: 32-39.
43. Commissaris RL, McCloskey TC, Harrington GM, Altman HJ. MR/Har and MNRA/Har Maudsley rat strains: differential response to chlordiazepoxide in a conflict task. Pharm Biochem Behav 1989; 32: 801-805. (Pubitemid 19162407)
44. Commissaris RL, Harrington GM, Altman HJ. Benzodiazepine anticonflict effects in Maudsley reactive (MR/Har) and non-reactive (MNRA/Har) rats. Psychopharmacology 1990; 100: 287-292. (Pubitemid 20052413)
45. Broadhurst PL. Experiments in psychogenetics. In Eysenck HJ (ed) Experiments in Personality. Routledge & Kegan Paul: London, UK. vol 1, pp 1-102, 1960.
46. Broadhurst PL. The Maudsley Reactive and Nonreactive strains of rats: A survey. Behav Genet 1975; 5: 299-319.